✦ LIBER ✦

Meta-analysis of the second collaborative study of adjuvant chemoendocrine therapy for breast cancer (acetbc) in patients with stage ii, estrogen-receptor-positive breast cancer

✍ Scribed by Minoru Yoshida; Osahiko Abe; Junichi Uchino; Kaneo Kikuchi; Rikiya Abe; Kohji Enomoto; Takeshi Tominaga; Atsuo Fukami; Keizo Sugimachi; Yasuo Nomura; Takao Hattori; Nobuya Ogawa

Publisher: Springer Japan
Year: 1997
Tongue: English
Weight: 734 KB
Volume: 4
Category: Article
ISSN: 1340-6868
DOI: 10.1007/bf02967062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views